Pulmonary Alveolar Hemorrhage after Clopidogrel Use for ST Elevation Myocardial Infarction

Area of Science:

• Cardiology
• Pulmonary Medicine
• Pharmacology

Background:

• Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard after percutaneous coronary intervention (PCI) for high-risk patients.
• While effective in reducing ischemic events, DAPT increases bleeding risk.
• Diffuse alveolar hemorrhage (DAH) is a rare but serious complication, often linked to glycoprotein IIb/IIIa inhibitors.

Purpose of the Study:

• To report a rare case of diffuse alveolar hemorrhage (DAH) following clopidogrel use after primary PCI.
• To highlight a potential adverse effect of clopidogrel in the context of PCI.

Main Methods:

• Case report of a 62-year-old male patient.
• Patient presented with ST-elevation myocardial infarction.
• Underwent primary PCI and received clopidogrel therapy.

Main Results:

• The patient developed diffuse alveolar hemorrhage (DAH) post-PCI.
• This complication occurred after the initiation of clopidogrel treatment.
• This case suggests a potential association between clopidogrel and DAH.

Conclusions:

• Diffuse alveolar hemorrhage (DAH) is a rare complication that can occur after percutaneous coronary intervention (PCI).
• This case highlights clopidogrel as a potential, albeit rare, cause of DAH.
• Clinicians should be aware of this potential adverse event in patients receiving DAPT after PCI.